Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Black Raspberry Confection in Preventing Oral Cancer in Healthy Volunteers

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
状態アクティブ、募集していない
スポンサー
Ohio State University Comprehensive Cancer Center

キーワード

概要

This clinical trial studies black raspberry confection in preventing oral cancer in healthy volunteers. Black raspberry contains ingredients that may prevent or slow the growth of certain cancers.

説明

PRIMARY OBJECTIVES:

I. To select an optimal black raspberry confection based on altered gene expression and chemical profiles in healthy individuals exposed to 3 black raspberry-based amorphous functional confections with modulated bioactive release rate at two doses (4 g and 8 g).

OUTLINE: Participants are randomized to 1 of 6 arms after 2 weeks.

ARM I: Participants receive black raspberry (BRB) confection 1 fast release orally (PO) 4-6 hours apart thrice daily (TID) for 2 weeks.

ARM II: Participants receive BRB confection 2 fast release PO 4-6 hours apart TID for 2 weeks.

ARM III: Participants receive BRB confection 1 intermediate release PO 4-6 hours apart TID for 2 weeks.

ARM IV: Participants receive BRB confection 2 intermediate release PO 4-6 hours apart TID for 2 weeks.

ARM V: Participants receive BRB confection 1 prolonged release PO 4-6 hours apart TID for 2 weeks.

ARM VI: Participants receive BRB confection 2 prolonged release PO 4-6 hours apart TID for 2 weeks.

日付

最終確認済み: 02/28/2019
最初に提出された: 10/09/2013
提出された推定登録数: 10/10/2013
最初の投稿: 10/13/2013
最終更新が送信されました: 03/17/2019
最終更新日: 03/18/2019
実際の研究開始日: 06/30/2013
一次完了予定日: 03/31/2020
研究完了予定日: 03/31/2020

状態または病気

Healthy Volunteers

介入/治療

Other: Fast release BRB confection

Other: Intermed release BRB confection

Other: Prolong release BRB confection

段階

段階 1

アームグループ

介入/治療
Experimental: Arm I (Fast release BRB confection 4g)
Participants receive one fast release BRB confection (4g) PO 4-6 hours apart thrice daily (TID) for 2 weeks.
Experimental: Arm II (Fast release BRB confection 8g)
Participants receive two fast release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
Experimental: Arm III (Intermed release BRBconfection 4g)
Participants receive one intermediate release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
Experimental: Arm IV (Intermed release BRBconfection 8g)
Participants receive two intermediate release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
Experimental: Arm V (Prolong release BRB confection 4g)
Participants receive one prolonged release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
Experimental: Arm VI (Prolong release BRB confection 8g)
Participants receive two prolonged release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.

適格基準

研究の対象となる年齢 18 Years に 18 Years
研究に適格な性別All
健康なボランティアを受け入れるはい
基準

Inclusion Criteria:

- Be healthy, free-living adults

- Be a non-smoker (defined as adults who have never smoked or who have not had a cigarette in the past ten years)

- Agree to consume a standardized vitamin/mineral supplement and avoid other nutrition and alternative supplements for the duration of the study

- Agree to follow a berry-restricted diet and to document any accidental consumption of restricted foods each day of the study

- Agree to abstain from mouthwashes

Exclusion Criteria:

- Have an active metabolic or digestive illness including malabsorptive disorders, renal insufficiency, hepatic insufficiency, cachexia, or short bowel syndrome

- Have an active or a recent history of any condition that causes altered immunity such as chronic inflammatory disease, autoimmune disorders, cancer, anemia, and blood dyscrasias

- Have a known allergy or food intolerance to ingredients in study products (black raspberries),other berries, wheat, or soy

- Are strict vegans (no consumption of animal, fish or egg products)

- Are planning to conceive, or are currently pregnant or lactating

- Are heavy alcohol consumers (defined as an average consumption of greater than 2 drinks/day)

- Have a history of oral cancer or currently undergoing treatment of oral cancer

- In the last month have had any active oral lesions or maladies or currently have any oral disease or obvious open sores in the oral cavity or surrounding the oral opening

- Have strong gag reflex or problems swallowing that prohibit buccal brushing of the oral cavity

- Have been on an antibiotic regime lasting for one week in the last 6 months

結果

主な結果の測定

1. Acceptance of candidate formulations, assessed using a 9 point hedonic scale (1 =dislike very much, 9 = like very much) [Up to day 14]

Compliance and safety of the confections will be evaluated using dietary and sensory questionnaires. The analysis of variance (ANOVA) style model accounting for the random effect of the individual subject and the fixed effect of the dissolution (amorphous confection form) group will be used to examine the effect of attribute data, gender, and age using a 9-point hedonic scale. The significant differences between means of the different groups will be examined using the Ryan-Einot-Gabriel-Welsch (REGW) multiple comparisons test.

2. Bioavailability index, defined as the average rank of BRB effect in anthocyanins, ellagic acid, urolithins, and quercetin derivatives [Up to day 14]

To select an optimal delivery vehicle & dose, a combination that results in any of 10 subjects having an adverse event will be eliminated in the 1st stage. In the 2nd and 3rd stages ANOVA style models accounting for the random effect of individual subject and the fixed effect of dose & release rate will be used to examine phytonutrient metabolite & gene expression. Using the multiple comparisons with the best procedure, any combination will be eliminated that is significantly worse than the best combination for a global index of bioavailability (stage 2) and gene expression effects (stage 3).

3. Gene expression index, defined as the average rank of BRB effect on expression of genes responsive to BRBs and important to smoking and inflammatory response [Up to day 14]

To select an optimal delivery vehicle & dose, a combination that results in any of 10 subjects having an adverse event will be eliminated in the 1st stage. In the 2nd and 3rd stages ANOVA style models accounting for the random effect of individual subject and the fixed effect of dose & release rate will be used to examine phytonutrient metabolite & gene expression. Using the multiple comparisons with the best procedure, any combination will be eliminated that is significantly worse than the best combination for a global index of bioavailability (stage 2) and gene expression effects (stage 3).

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge